As we approach our next phase of progress and innovation, we’re excited to share some important news: by January 1, 2026, EpiphanyRx and Navitus will come together as one brand - Navitus. Going to market as a unified PBM brand is the next phase of our continued growth together. Brand changes often raise questions, so we’ve put together this Fast Five to address some key considerations and explain why this change is happening.
Navigating the current complex landscape of weight management programs and tools can be overwhelming. In this Fast Five, we’ll address five common questions regarding GLP-1 medications and alternative healthy weight solutions such as Noom and Virta.
Pharmacy Benefit Managers (PBMs) play a crucial role in managing your organization’s and its members’ healthcare costs, but it is important to understand how they operate and impact your plan’s benefits. We're sharing five key questions to ask your PBM to ensure you are getting the most out of your prescription drug coverage provider.
Employers are tired of feeling confused or overwhelmed by the data provided from their pharmacy benefit manager (PBM). In our latest Fast Five post, we’re uncovering what makes up a stellar reporting package from a PBM, including essential data points for employer groups and the pitfalls of overwhelming clients with too much data.
We’ve been seeing employers hesitate to move to a new pharmacy benefit manager (PBM) for fear of the impact on their members. In this Fast Five, we share what it’s really like for employers and their employees to move to a better PBM (like EpiphanyRx) with a supportive transition approach.
EpiphanyRx performed a study to identify drivers contributing to recent increased ADHD medication use within commercial employer groups. Read more about our discoveries.
In this Fast Five, we revisit biosimilars - still a hot industry topic. We explore biosimilar pricing and the incentives motivating drug manufacturers and pharmacy benefit managers (PBMs). We discuss formulary decisions including placement of biosimilars and removal of brand Humira®. To help us break down this complicated topic, we consulted our clinical expert, Janelle Sheen, Senior Director of Clinical Strategy.
GPOs began emerging in 2019 and continue to grow. In this Fast Five, we share five insights on transparency in the age of GPOs and what to keep in mind when you are evaluating different PBMs.
EpiphanyRx studied the refill success rates for preventive medications as a measure of adherence in HDHPs across our book of business. Learn more about what we discovered.
